Vaccines,
Год журнала:
2024,
Номер
12(12), С. 1382 - 1382
Опубликована: Дек. 7, 2024
Influenza
poses
a
significant
global
health
challenge
due
to
its
rapid
mutation
and
antigenic
variability,
which
often
leads
seasonal
epidemics
frequent
outbreaks.
Traditional
vaccines
struggle
offer
comprehensive
protection
because
of
mismatches
with
circulating
viral
strains.
The
development
broad-spectrum
vaccine
is
therefore
crucial.
This
paper
explores
the
potential
mRNA
technology
address
these
challenges
by
providing
swift,
adaptable,
broad
protective
response
against
evolving
influenza
We
detail
mechanisms
variation
in
viruses
discuss
design
production,
enhanced
immunogenicity,
encoding
multiple
antigens,
safety
stability
compared
traditional
methods.
By
leveraging
advantages,
represent
revolutionary
approach
prevention,
potentially
offering
significantly
improving
management
strategies.
Journal of Nanobiotechnology,
Год журнала:
2024,
Номер
22(1)
Опубликована: Ноя. 14, 2024
RNA
therapeutics,
such
as
mRNA,
siRNA,
and
CRISPR–Cas9,
present
exciting
avenues
for
treating
diverse
diseases.
However,
their
potential
is
commonly
hindered
by
vulnerability
to
degradation
poor
cellular
uptake,
requiring
effective
delivery
systems.
Lipid
nanoparticles
(LNPs)
have
emerged
a
leading
choice
in
vivo
delivery,
offering
protection
against
degradation,
enhanced
facilitation
of
endosomal
escape.
LNPs
encounter
numerous
challenges
targeted
vivo,
demanding
advanced
particle
engineering,
surface
functionalization
with
targeting
ligands,
profound
comprehension
the
biological
milieu
which
they
function.
This
review
explores
structural
physicochemical
characteristics
LNPs,
in-vivo
fate,
customization
therapeutics.
We
highlight
quality-by-design
(QbD)
approach
beyond
liver,
focusing
on
biodistribution,
immunogenicity,
toxicity.
In
addition,
we
explored
current
strategies
associated
ensuring
repeated-dose
efficacy,
safety,
tissue-specific
gene
delivery.
Furthermore,
provide
insights
into
clinical
applications
various
classes
diseases
finally
prospects
Bioanalysis,
Год журнала:
2025,
Номер
unknown, С. 1 - 16
Опубликована: Фев. 3, 2025
Undruggable
targets
account
for
roughly
85%
of
human
disease-related
and
represent
a
category
therapeutic
that
are
difficult
to
tackle
with
traditional
methods,
but
their
considerable
clinical
importance.
These
generally
defined
by
planar
functional
interfaces
the
absence
efficient
ligand-binding
pockets,
making
them
unattainable
conventional
pharmaceutical
strategies.
The
advent
oligonucleotide-based
proteolysis-targeting
chimeras
(PROTACs)
has
instilled
renewed
optimism
in
addressing
these
challenges.
PROTACs
facilitate
targeted
degradation
undruggable
entities,
including
transcription
factors
(TFs)
RNA-binding
proteins
(RBPs),
via
proteasome-dependent
mechanisms,
thereby
presenting
novel
approaches
diseases
linked
targets.
This
review
offers
an
in-depth
examination
recent
progress
integration
PROTAC
technology
oligonucleotides
target
traditionally
proteins,
emphasizing
design
principles
mechanisms
action
innovative
PROTACs.
Molecular Therapy — Methods & Clinical Development,
Год журнала:
2025,
Номер
33(1), С. 101436 - 101436
Опубликована: Фев. 16, 2025
Lipid
nanoparticles
(LNPs)
are
now
highly
effective
transporters
of
nucleic
acids
to
the
liver.
This
liver-specificity
is
largely
due
their
association
with
certain
serum
proteins,
most
notably
apolipoprotein
E
(ApoE),
which
directs
them
liver
cells
by
binding
low-density
lipoprotein
(LDL)
receptors
on
hepatocytes.
The
liver's
distinct
anatomy,
its
various
specialized
cell
types,
also
influences
how
LNPs
taken
up
from
circulation,
cleared,
and
they
in
delivering
treatments.
In
this
review,
we
consider
factors
that
facilitate
LNP's
targeting
explore
latest
advances
liver-targeted
LNP
technologies.
Understanding
targeted
can
help
for
design
optimization
nanoparticle-based
therapies.
Comprehension
cellular
interaction
biodistribution
not
only
leads
better
treatments
diseases
but
delivers
insight
directing
other
tissues,
potentially
broadening
range
therapeutic
applications.
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Фев. 27, 2025
Diabetes,
affecting
over
10.5%
of
the
global
population,
leads
to
severe
health
complications
and
economic
burdens,
highlighting
urgent
need
for
effective
therapeutic
approaches.
Current
treatments
are
often
insufficient,
prompting
exploration
novel
agents
delivery
mechanisms.
This
study
addresses
this
gap
by
investigating
roles
L-arginine
(identified
as
a
target
drug
candidate
through
network
pharmacology)
in
diabetes
management,
while
also
evaluating
lipid
nanocarriers
synthesized
from
fenugreek
seed
oil
improved
delivery.
Our
docking
analyses
revealed
L-arginine's
strong
interactions
with
diabetes-target
genes
(CYP1A2,
CYP2C19,
NFKB),
multiple
hydrogen
bonds
binding
energies
ranging
−
7.2
8.9
kcal/mol.
Encapsulated
nanoparticles
were
characterized
using
UV-Visible
spectroscopy,
showing
absorbance
peaks
at
415
nm
simple
521
L-arginine-loaded
nanoparticles.
Scanning
electron
microscopy
confirmed
an
average
nanoparticle
size
100.2
nm,
zeta
potential
analysis
indicated
neutral
surface
charge
(−
9.37
mV).
Antioxidative
activity
showed
84.44%
inhibition
IC50
value
40.5
µg/mL
The
inhibited
albumin
denaturation
81.10%
alpha-amylase
89.30%,
surpassing
metformin
(78.43%
1000
µg/mL).
Hemolysis
percentage
was
minimal
10.54%.
These
findings
demonstrate
anti-diabetic
agent
highlight
efficacy
innovative
systems,
providing
foundation
advancing
interventions
against
diabetes.
Pharmaceutics,
Год журнала:
2025,
Номер
17(3), С. 388 - 388
Опубликована: Март 18, 2025
Neuroinflammation
within
the
central
nervous
system
(CNS)
is
a
primary
characteristic
of
CNS
diseases,
such
as
Parkinson’s
disease,
Alzheimer’s
disease
(AD),
amyotrophic
lateral
sclerosis,
and
mental
disorders.
The
excessive
activation
immune
cells
results
in
massive
release
pro-inflammatory
cytokines,
which
subsequently
induce
neuronal
death
accelerate
progression
neurodegeneration.
Therefore,
mitigating
neuroinflammation
has
emerged
promising
strategy
for
treatment
diseases.
Despite
advancements
drug
discovery
development
novel
therapeutics,
effective
delivery
these
agents
to
remains
serious
challenge
due
restrictive
nature
blood–brain
barrier
(BBB).
This
underscores
need
develop
system.
Recent
studies
have
identified
oral
lipid
nanoparticles
(LNPs)
approach
efficiently
deliver
drugs
across
BBB
treat
neurological
review
aims
comprehensively
summarize
recent
LNPs
designed
controlled
therapeutic
modulation
diseases
through
administration.
Furthermore,
this
addresses
mechanisms
by
overcome
biological
barriers
evaluate
their
clinical
implications
efficacy
context
systems.
Specifically,
it
focuses
on
LNP
formulations
that
facilitate
administration,
exploring
potential
enhance
bioavailability,
improve
targeting
precision,
alleviate
or
manage
symptoms
associated
with
range
Vaccines,
Год журнала:
2025,
Номер
13(3), С. 327 - 327
Опубликована: Март 19, 2025
Background/Objectives:
An
overwhelming
burden
to
clinics,
herpes
zoster
(HZ),
or
shingles,
is
a
painful
disease
that
occurs
frequently
among
aged
individuals
with
varicella-zoster
virus
(VZV)
infection
history.
The
cause
of
shingles
the
reactivation
dormant
VZV
in
dorsal
root
ganglia/cranial
nerves
human
body.
Patients
HZ
experience
sharp,
intense,
electric
shock-like
pain,
which
makes
their
health-related
quality
life
(HRQoL)
extremely
low.
Methods:
Various
mRNA
constructs
were
designed
based
on
intracellular
organelle-targeting
strategies
and
AI
algorithm-guided
high-throughput
automation
platform
screening
then
synthesized
by
vitro
transcription
encapsulated
four-component
lipid
nanoparticles
(LNPs).
Immunogenicity
was
evaluated
naïve
mouse
model,
long-term
VZV-primed
model.
Safety
modified
“nestlet
shredding”
method
for
potential
adverse
effects
induced
vaccines.
Comparison
between
muscular
intradermal
administrations
conducted
using
different
inoculated
approaches
as
well.
Results:
best
vaccine
candidate,
CVG206,
showed
robust
humoral
cellular
immune
responses,
durable
protection,
fewest
effects.
CVG206
administered
intradermally
revealed
at
least
threefold
higher
responses
compared
intramuscular
vaccination.
manufactured
lyophilized
patch
demonstrated
good
thermal
stability
2–8
°C
during
9
months
storage.
Conclusions:
possesses
remarkable
immunogenicity,
safety,
stability,
its
effectiveness
could
even
be
further
improved
administration,
revealing
promising
candidate
future
clinical
studies.
Frontiers in Nanotechnology,
Год журнала:
2025,
Номер
7
Опубликована: Март 19, 2025
Ribonucleic
acid-lipid
nanoparticle
(RNA-LNP)
therapeutics,
a
powerful
nanomedicine
platform,
have
already
demonstrated
their
efficacy
in
diverse
applications.
Their
improved
stability
and
are
exemplified
by
successful
rapid
launch
of
mRNA
vaccines,
as
well
marketed
siRNA
drug
product.
Beyond
infectious
diseases,
RNA-LNPs
show
promise
addressing
unmet
needs
women’s
health,
for
instance,
gynecologic
cancers
(e.g.,
ovarian,
cervical)
novel
treatments
conditions
such
osteoporosis,
endometriosis,
congenital
disorders.
However,
important
challenges
persist,
including
off-target
effects,
immunogenicity,
potential
risks
ethical
issues
application
pregnant
or
lactating
women.
This
review
summarizes
current
key
preclinical
clinical
progress,
discusses
targeting
strategies
LNPs
active
passive
delivery),
presents
knowledge
on
RNA-LNP
safety
non-pregnant
women
neonates
vulnerable
populations.
As
technologies
evolve
–
with
relevant
animal
models,
next-generation
RNA
platforms
lipid
chemistries
they
can
hold
significant
transforming
care
health
through
safer,
effective,
personalized,
innovative
curative
interventions.
